GT Biopharma IncChange company Symbol lookupSelect an option...GTBP GT Biopharma IncTRIRF Triterras IncAIC Arlington Asset Investment CorpLCID Lucid Group IncAMAT Applied Materials Inc$DWCPAP DJTSM US PaperCMMB Chemomab Therapeutics LtdDLTR Dollar Tree IncBAC Bank of America CorpKW Kennedy-Wilson Holdings IncGo
Change company Symbol lookup
Select an option...
GTBP GT Biopharma Inc
TRIRF Triterras Inc
AIC Arlington Asset Investment Corp
LCID Lucid Group Inc
AMAT Applied Materials Inc
$DWCPAP DJTSM US Paper
CMMB Chemomab Therapeutics Ltd
DLTR Dollar Tree Inc
BAC Bank of America Corp
KW Kennedy-Wilson Holdings Inc
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Small Cap Value
Company profileGT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patients own natural killer cells (NK) cells. GTB-3550 is its TriKE product candidate which is a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The GTB-3550 Phase 1 clinical trial for treatment of patients with CD33-expression. It is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease, such as for the treatment of patients infected by the human immunodeficiency virus.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q1 ending 03/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q1 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced May 15, 2023 | -$0.01 | Q1 Consensus of 2 analysts | -$0.15 | Difference from consensus | 93.10% | Q2 Earnings will announce | (Unconfirmed) August 9, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
GTBP's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.